Satoru Iwasa
Tokyo, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 158 publications
PD-L1 expression and survival in unresectable/recurrent gastric cancer treated by 1st-line treatment without immune checkpoint inhibitors: JCOG1013A1.
Journal: British journal of cancer
Published: March 14, 2026
Phase Ib Basket Expansion Trial and Alternative-Schedule Dose-Escalation Study of ATR Inhibitor Elimusertib in Advanced Solid Tumors with DNA Damage Response Defects.
Journal: Cancer discovery
Published: November 19, 2024
Impact of taxanes after PD-1 blockade exposure in advanced esophageal squamous cell carcinoma.
Journal: Esophagus : official journal of the Japan Esophageal Society
Published: June 07, 2024
Correction to: Phase I study of the anti‑TIGIT antibody tiragolumab in combination with atezolizumab in Japanese patients with advanced or metastatic solid tumors.
Journal: Cancer chemotherapy and pharmacology
Published: March 31, 2024
Safety and Efficacy of Encorafenib, Binimetinib, and Cetuximab for BRAFV600E-Mutant Metastatic Colorectal Cancer: Results of the Japanese Expanded Access Program.
Journal: Clinical colorectal cancer
Published: December 05, 2023
Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial.
Journal: Nature medicine
Published: November 09, 2023
Preoperative docetaxel, cisplatin, and 5-fluorouracil for resectable locally advanced esophageal and esophagogastric junctional adenocarcinoma.
Journal: Esophagus : official journal of the Japan Esophageal Society
Published: October 26, 2023
Retrospective Analysis of Definitive Chemoradiotherapy With FOLFOX in Patients With Esophageal Cancer Intolerant to Cisplatin.
Journal: In vivo (Athens, Greece)
Published: October 09, 2023
Last Updated: 09/26/2026